Medivation Announces Positive New Efficacy Data From Phase 1-2 Trial of MDV3100 in Advanced Prostate Cancer Patients
-- Findings Presented at American Society of Clinical Oncology 2009 Annual Meeting and Included in Best of ASCO(R) Educational Program --
SAN FRANCISCO, June 2 /PRNewswire-FirstCall/ -- Medivation, Inc. (Nasdaq: MDVN ) today announced the presentation of new clinical results from a Phase 1-...
Investigational Genetic Test May Help Address Common Problems in Prostate Cancer Diagnosis
- Eight Studies Presented at Leading Urology Meeting Show that Simple Urine Test for PCA3 Gene May Improve Accuracy of Prostate
Cancer Detection, Reduce Unnecessary Biopsies -
- Gen-Probe to Begin Pivotal Clinical Study in Effort to Gain U.S. Regulatory Approval -
SAN DIEGO, ...
Gen-Probe and DiagnoCure Amend Collaboration Agreement Surrounding PCA3-Based Prostate Cancer Tests
Gen-Probe invests US$5 million in DiagnoCure
SAN DIEGO and QUEBEC CITY, April 29 /PRNewswire-FirstCall/ -- Gen-Probe Incorporated (Nasdaq: GPRO ) and DiagnoCure Inc. (TSX: CUR) today announced that the companies have signed an amendment to their 2003 license agreement, establishing new FDA...
Study Results Present Paradigm Shift; REDUCE Trial Shows New Hope for the Risk Reduction of Prostate Cancer
WASHINGTON, April 29 /PRNewswire-USNewswire/ -- The recent announcement of the REDUCE trial results at the American Urological Association annual meeting in Chicago brings optimism to the prostate
cancer community as dutasteride (Avodart), a drug used to treat benign prostatic hyperplasia, has...
Prostate Cancer Immunotherapy Significantly Prolongs Survival in Men With Advanced Prostate Cancer
Phase 3 IMPACT Trial Results to be presented during late-breaking session at AUA Annual Scientific Meeting
CHICAGO, April 28 /PRNewswire-USNewswire/ -- Sipuleucel-T (Provenge), an experimental immunotherapy improved survival in men with metastatic disease, according to new results to be pr...
Data Presented at AUA Demonstrate PROVENGE Significantly Prolongs Survival for Men With Advanced Prostate Cancer in Pivotal Phase 3 IMPACT Study
- Extended Median Survival by 4.1 Months and Increased 3-Year Survival by 38 Percent Compared to Placebo -
- First Active Cellular Immunotherapy for Cancer to Prolong Survival -
- Company to Host Webcast at 5:30 pm ET -
CHICAGO and SEATTLE, April 28 /PRNewswire-FirstCall/ -- Dendreo...
Men Treated for Localized Prostate Cancer Could Benefit From Pomegranate Juice Consumption
LINTHICUM, Md., April 27 /PRNewswire-USNewswire/ -- Pomegranate juice may slow the progression of post-treatment prostate
cancer recurrence, according to new long-term research results being presented at the 104th Annual Scientific Meeting of the American Urological Association (AUA). Researcher...
Data Presented at AACR Annual Meeting Show Anti-Tumor Activity of Peregrine's Fully Human Anti-PS Antibody in Prostate Cancer Model
-Preclinical Results Further Validate Significant Anti-Tumor Potential of Fully Human Anti-PS Antibodies and Expand the Company's PS-Targeting Platform-
-Treatment with Mouse Equivalent to the Human Antibody Inhibited Tumor Growth in a Prostate
Cancer Model by More than 90%-
EAU Position Statement on Screening for Prostate Cancer
ARNHEM, The Netherlands, April 16 /PRNewswire/ -- The European
Association of Urology (EAU) has taken into consideration the recent
scientific information on randomised screening studies on prostate
(SchrÃ¶der et al, NEJM 2009). Based on the results of the European Randomised
Study for ...
A Joint Statement From America's Prostate Cancer Advocacy, Education, and Support Organizations
WASHINGTON, March 23 /PRNewswire-USNewswire/ -- Since 1993, when the PLCO trial was started, we have awaited the results of this trial with eager anticipation, as have others. The initial report of the results of this study -- and those of a comparable European trial -- published last week in the ...
Leader in Prostate Health Urges Prostate Cancer Screening in Face of Contradicting Data
DENVER, March 18 /PRNewswire-USNewswire/ -- New data evaluating the impact of screening on mortality provides mixed messages on the value of prostate
cancer screening. The Prostate
Conditions Education Council (PCEC), a national organization committed to men's health and a leader in prostate
PSA Screening Cuts Deaths by 20%, Says World's Largest Prostate Cancer Study
STOCKHOLM, Sweden, March 18 /PRNewswire/ --
- Attn: Healthcare Editors
Screening for prostate
cancer can reduce deaths by 20%, according to the
results of the European Randomized Study of Screening for Prostate
(ERSPC) published online 1700 hours CET 18 March (NEJM, Online...
Walter Reed Army Medical Center offers HIFU for Qualifying Men with Locally Recurrent Prostate Cancer in a Phase III Clinical Trial
CHARLOTTE, N.C., March 16 /PRNewswire/ -- Walter Reed Army Medical Center is the latest institution to be added to a number of academic centers involved in a clinical trial that is investigating the safety and efficacy of High Intensity Focused Ultrasound (HIFU) using the Sonablate(R) 500 for the ...
Freezing Prostate Cancer Does a Man's Body Good
Minimally Invasive "Lumpectomy" -- as Effective as Surgery -- Preserves Sexual and Urinary Function; Related Study Shows 3-D Mapping Biopsy Changed Patients' Management 70 Percent of the Time
SAN DIEGO, March 9 /PRNewswire-USNewswire/ -- The so-called "male lumpectomy" -- a minimally invasive...
Cardium's InnerCool Announces Positive Benefits of Cooling During Robotic-Assisted Prostate Surgery Published in Urology
SAN DIEGO, March 9 /PRNewswire-FirstCall/ -- Cardium Therapeutics (NYSE Alternext US: CXM) and its operating unit InnerCool Therapies, Inc., today reported that positive clinical findings demonstrating faster recovery of urinary continence using localized manual cooling techniques during robotic-a...
Ascenta Therapeutics Announces Positive Preliminary Results with AT-101 in Docetaxel Refractory Prostate Cancer
- Data presented today at American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium -
MALVERN, Pa., Feb. 27 /PRNewswire/ -- Ascenta Therapeutics announced today positive preliminary results from its Phase II study of AT-101 in combination with docetaxel and prednisone (D/P)...
Researchers Discover Metabolite Linked to Aggressive Prostate Cancer
Finding could lead to test to help guide treatment decisions
ANN ARBOR, Mich., Feb. 11 /PRNewswire-USNewswire/ -- Researchers from the University of Michigan Comprehensive Cancer Center have identified a panel of small molecules, or metabolites, that appear to indicate aggressive prostate
VIDEO from Medialink and International HIFU: New Prostate Cancer Procedure Being Tested in US Clinical Trials
NEW YORK, Jan. 29 /PRNewswire/ -- According to the American Cancer Association, prostate
cancer affects one in six men in the U.S. and is the second leading cause of cancer deaths in men. When caught and treated early, survival rates can be more than 90 percent, making swift treatment key.
Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer
OSLO, Norway, January 14 /PRNewswire-FirstCall/ --
- Results Highlight the Potential of Alpharadin to Treat Bone Metastases
in Major Cancer Indications
Algeta ASA (OSE: ALGETA), the cancer therapeutics company, announces that
with the results of the BC1-04 study reported today i...
Medivation Completes Enrollment of Phase 1-2 Trial of MDV3100 in Castration-Resistant Prostate Cancer Patients
SAN FRANCISCO, Dec. 17 /PRNewswire-FirstCall/ -- Medivation, Inc.
(Nasdaq: MDVN ) today announced that it has completed patient enrollment in a
Phase 1-2 dose-escalation clinical trial of MDV3100, its novel androgen
receptor antagonist, in castration-resistant prostate
cancer patients, and
Isis Announces That OGX-011 Has Shown Overall Survival Advantage in Prostate Cancer Compared to Standard Therapy in a Randomized Phase 2 Study
CARLSBAD, Calif., Dec. 3 /PRNewswire-FirstCall/ -- Isis Pharmaceuticals,
Inc. (Nasdaq: ISIS ) announced today that OncoGenex Pharmaceuticals, Inc.
provided positive survival results from a randomized Phase 2 clinical trial of
OGX-011 in combination with docetaxel and prednisone ("the OGX-011 arm...
SELECT TRIAL Used Selenomethionine Instead of High-Selenium Yeast, SelenoExcell(R) - Previous Research has Shown SelenoExcell(R) Supplementation to Reduce Lung, Colon and Prostate Cancers by as Much as 63%, Says Cypress Systems, Inc.
FRESNO, Calif., Oct. 29 /PRNewswire/ -- Cypress Systems, Inc., a Fresno
CA based biotechnology company, emphasizes that the SELECT TRIAL results --
that were announced yesterday -- used a form of selenium known as
selenomethionine. The SELECT TRIAL found no effects of either
Gene Found Activated in 70% of Prostate Cancer Cases, George Washington University Medical Center Scientists Report
DRS. PATRICIA BERG AND ARNOLD SCHWARTZ LED TEAM, Article in Modern
Pathology set for print publication January 2009
BERG HAD ALSO DISCOVERED SAME GENE'S ACTIVATION IN MAJORITY OF BREAST
WASHINGTON, Oct. 24 /PRNewswire-USNewswire/ -- A gene has been found
activated in 70% of pr...
BN ImmunoTherapeutics Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
125 Patient, Prospective Randomized Placebo-Controlled Phase II Study Shows Statistically Significant Improved Overall Survival.
MOUNTAIN VIEW, California, October 7 /PRNewswire/ -- BN
ImmunoTherapeutics has now evaluated the mature Phase II data from the
Bavarian Nordic Announces Positive Mature Phase II Results From Newly Acquired Prostate Cancer Vaccine
KVISTGÃ…RD, Denmark, October 7 /PRNewswire-FirstCall/ --
- 125 Patient, Prospective Randomized Placebo-Controlled Phase II Study
Shows Statistically Significant Improved Overall Survival
Bavarian Nordic has now evaluated the mature phase II data from the
Debiopharm Moves Towards a New 6-Month Formulation of Decapeptyl(R) to Further Help Prostate Cancer Patients
LAUSANNE, Switzerland, September 25 /PRNewswire/ -- Debiopharm Group
(Debiopharm), a global biopharmaceutical development specialist that
focuses on serious medical conditions and particularly oncology, announces
the filing of an application with the European Agencies for the approval of
High Intensity Focused Ultrasound for Locally Recurrent Prostate Cancer Following External Beam Radiation Therapy Investigated in Phase III Clinical Study
CHARLOTTE, N.C., Sept. 11 /PRNewswire/ -- In a new study, men with
locally recurrent prostate
cancer may be able to receive a promising
investigational ultrasound treatment option.
A Phase III clinical trial at Specialists in Urology, located in North
Naples, FL, is investigating the safety ...
FluoroPharma, Inc. to Report Preclinical Data on Alzheimer's Disease and Prostate Cancer PET Imaging Agents
BOSTON, Sept. 8 /PRNewswire/ -- FluoroPharma, Inc. announced today that
Dr. David Elmaleh, FluoroPharma's founder and Chief Scientific Advisor,
will report on two preclinical studies demonstrating the potential of novel
Positron Emission Tomography (PET) molecular imaging agents for detection
Morse CyberKnife CEO James G. Schwade, M.D. Announces Non-Surgical Treatment With CyberKnife Radiosurgery for Prostate Cancer
September is Prostate
Cancer Awareness Month
MIAMI and PALM BEACH, Fla., Sept. 2 /PRNewswire/ -- September is
Prostate Cancer Awareness Month, and the CyberKnife Centers of Miami and
Palm Beach announce a revolutionary new way to treat prostate
without surgery and long tre...
Task Force Says Men Age 75 and Older Should Not Be Screened For Prostate Cancer
/CAUTION -- ADVANCE FOR RELEASE AT 5 P.M. EDT MONDAY, AUG. 4/
/ADVANCE/ ROCKVILLE, Md., Aug. 4 -- Men age 75 and older should not be
screened for prostate
cancer, and younger men should discuss the benefits
and harms of the prostate-specific antigen (PSA) test with their clinicians
Halozyme Therapeutics Announces Positive Findings With Pegylated Enzyme in Prostate Cancer Models
- Systemic treatment with chemotherapy and pegylated enzyme produces significantly enhanced survival compared to chemotherapy alone - - Pegylated enzyme well tolerated -
SAN DIEGO, July 22 /PRNewswire-FirstCall/ -- Halozyme Therapeutics,
Inc. (Nasdaq: HALO ), a biopharma...
Nemours Center for Childhood Cancer Research Team at the Alfred I. duPont Hospital for Children Identifies the Function of a Biomarker Present in Prostate Cancer Cells: New Insight into Therapeutic Benefit for Patients with Advanced Prostate Cancer
WILMINGTON, Del., July 17 /PRNewswire/ -- The research team at the
Nemours Center for Childhood Cancer Research (NCCCR), a newly established
division of Nemours Biomedical Research at the Alfred I. duPont Hospital
for Children has discovered that the biomarker called prostate
Dendreon Initiates Phase 2 Trial of PROVENGE in Patients With Localized Prostate Cancer Prior to Surgery
SEATTLE, July 16 /PRNewswire-FirstCall/ -- Dendreon Corporation
(Nasdaq: DNDN ) today announced that the Company has initiated a Phase 2
trial of PROVENGE(R) (sipuleucel-T), Dendreon's investigational active
cellular immunotherapy for the treatment of prostate
cancer, in men with
Sonablate(R) International HIFU Registry is the First Worldwide HIFU Clinical Registry for Prostate Cancer Treatments
CHARLOTTE, N.C., July 9 /PRNewswire/ -- USHIFU, LLC, a global leader in
non invasive high intensity focused ultrasound (HIFU) technology, is proud
to announce sponsorship of the Sonablate(R) International HIFU Registry
(SIHR), along with co-sponsors Misonix, Inc. (Nasdaq: MSON ) and Takai
ABC News NIGHTLINE Features HIFU with Sonablate(R) 500 as Non Invasive Treatment Option for Prostate Cancer
Segment fails to mention ongoing FDA-approved HIFU clinical trials in the
United States and abundant clinical data on HIFU outcomes and experience
CHARLOTTE, N.C., June 27 /PRNewswire/ -- USHIFU, LLC, the exclusive
distributor of the minimally invasive Sonablate(R) 500 for prostate
Leading Academic Institutions Collaborate on 800-Patient Study of Effectiveness of Cryoablation for Men With Recurrent Prostate Cancer
Cryoablation Offers Second Chance for Patients Whose Cancer Returns after Radiation
IRVINE, Calif., June 6 /PRNewswire-FirstCall/ -- Endocare, Inc.
(Nasdaq: ENDO ), an innovative medical device company providing minimally
invasive technologies for tissue and tumor...
BN ImmunoTherapeutics Starts Clinical Trials With Prostate Cancer Vaccine
MOUNTAIN VIEW, California, June 4 /PRNewswire-FirstCall/ -- BN
ImmunoTherapeutics, Inc. has initiated Phase I/II clinical studies with its
therapeutic vaccine candidate against prostate
A Phase I/II safety and tolerability study in 18 male patients with
non-metastatic as well as horm...
Medivation Announces Presentation of Positive MDV3100 Clinical Data in Castration-Resistant Prostate Cancer Patients at 44th ASCO Annual Meeting
- Observed Dose-Response Trends Suggest Improved Efficacy with Higher Doses - - Dose Escalation Ongoing -
SAN FRANCISCO and CHICAGO, June 2 /PRNewswire-FirstCall/ -- Medivation,
Inc. (Nasdaq: MDVN ) today announced that data from an ongoing...
Interim Phase 1/2 Data of Ipilimumab in Prostate Cancer Presented at American Society of Clinical Oncology Annual Meeting
PRINCETON, N.J., June 2 /PRNewswire-FirstCall/ -- Medarex, Inc.
(Nasdaq: MEDX ) today announced interim results from a Phase 1/2 trial of
ipilimumab, an investigational oncology immunotherapy, as monotherapy or in
combination with radiotherapy in patients with metastatic castration
Research Explains How Advanced Prostate Cancer Becomes Resistant to Androgen-Deprivation Therapy
Findings suggest androgen production occurs within metastatic prostate
SEATTLE, June 2 /PRNewswire/ -- For the past 70 years the treatment of
choice for advanced, metastatic prostate
cancer has been
androgen-deprivation therapy. That is, the suppression ...